Lamotrigine Accord

Lamotrigine, the active ingredient in Lamotrigine Accord, is an anticonvulsant presented as a tablet for oral use. It works by inhibiting voltage‑gated sodium channels, thereby reducing neuronal excitability. Clinicians prescribe it to control various seizure types and to maintain mood stability in patients with bipolar disorder and is approved in the European Union for these indications.

GNH USA supplies Lamotrigine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory conformity for global distribution.

Lamotrigine is an oral anticonvulsant that modulates neuronal excitability in seizure disorders and mood stabilization.

- Epilepsy (focal seizures): Reduces frequency and severity of partial seizures. - Generalized tonic‑clonic seizures: Helps prevent seizure recurrence in primary generalized epilepsy. - Bipolar disorder (maintenance therapy): Decreases risk of mood episode recurrence and supports long‑term mood stability.

Lamotrigine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: Light‑headed sensation, especially at treatment initiation. - Headache: Mild to moderate intensity. - Nausea: Gastrointestinal discomfort or upset stomach. - Rash: Non‑serious skin irritation or maculopapular eruptions. - Insomnia: Difficulty falling or staying asleep. - Fatigue: Generalized tiredness or lack of energy.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: Severe skin reaction with blistering and mucosal involvement. - Toxic epidermal necrolysis: Life‑threatening skin detachment. - Aseptic meningitis: Inflammation of the meninges without infection. - Blood dyscrasias: Agranulocytosis, neutropenia, or thrombocytopenia. - Hepatotoxicity: Elevated liver enzymes or liver injury. - Suicidal ideation: Emergence or worsening of depressive thoughts.

When prescribing Lamotrigine, clinicians should observe several safety considerations to minimize risks.

- Initiate therapy gradually: Start with low dose and increase slowly to reduce rash risk. - Monitor skin reactions: Discontinue immediately if a widespread or severe rash develops. - Assess hepatic function: Use caution in patients with liver impairment. - Review concomitant medications: Certain drugs can alter lamotrigine plasma levels. - Pregnancy and lactation: Weigh benefits against unknown fetal risk; consult specialist. - Store at ambient temperature: Keep below 25 °C in original packaging, protect from moisture.

Lamotrigine’s plasma concentration can be affected by several co‑administered medicines, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Valproic acid: Increases lamotrigine levels markedly, raising risk of severe rash. - Carbamazepine, phenytoin, phenobarbital: Decrease lamotrigine concentrations, potentially reducing efficacy.

Moderate Interactions (Monitor Closely): - Oral contraceptives: Reduce lamotrigine clearance, may necessitate dose increase. - Serotonergic agents (e.g., SSRIs, SNRIs): May heighten risk of serotonin syndrome. - Other antiepileptic drugs (e.g., levetiracetam): May require therapeutic monitoring. - Antacids containing aluminum or magnesium: Can slightly lower absorption.